Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.
For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.
StrongSupportsVERY_HIGH confidence
The Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial... observed a 13% reduction in major adverse cardiovascular events (MACE) and a significant reduction in nephropathy progression... The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Outcome Study 6 (SUSTAIN-6) trial... demonstrated a 26% reduction in MACE.
Why this rating
Based on large-scale randomized controlled trials (LEADER, SUSTAIN-6).
Source
Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management
Adeshpal Singh et al. · Cureus · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →